Proactive - Interviews for investors

XanaMIA results: What's next for Actinogen Medical?
Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged over 75, although the primary endpoint was not achieved across the overall trial population. Gourlay highlighted a statistically significant difference in complete disease stabilisation among older participants, with 40% of patients receiving Xanamem showing no disease progression compared with 22% in the placebo group. The CEO also discussed the reported 30% slowing of Alzheimer's disease progression among patients older than 75, comparing the results with those observed for intravenous antibody therapies. Gourlay explained why the stronger response in older patients could be consistent with Xanamem's mechanism of action, which targets an enzyme involved in cortisol production in the brain. Looking ahead, Actinogen Medical is continuing its open-label extension study, with an expanded dataset expected in early 2027. Gourlay discussed the encouraging preliminary observations from 29 participants and the company's plans to assess results from at least 100 patients. With A$18.9 million in cash, Actinogen Medical also intends to engage with potential pharmaceutical development partners and regulators before committing further expenditure to a Phase 3 programme. Watch the full interview to hear Dr Steven Gourlay explain the XanaMIA results, the opportunity in older Alzheimer's patients and the potential next steps for Xanamem. For more biotechnology, healthcare and ASX company interviews, visit Proactive's YouTube channel. Give this video a like, subscribe to the channel and enable notifications so you don't miss future updates. #ActinogenMedical #AlzheimersDisease #Xanamem #XanaMIA #AlzheimersResearch #ClinicalTrials #Biotechnology #DrugDevelopment #ASXACW #HealthcareStocks #Phase3Trials #Neuroscience #ProactiveInvestors
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
